Introduction
Endometrial carcinoma is the most common malignancy of the female genital tract and is a growing number of in incidence, especially a high incidence rate in China. 1, 2 The mortality of endometrial carcinoma is only inferior to ovarian and cervical cancers and is presently increasing annually. 3 In recent years, The Cancer Genome Atlas (TCGA) database issued a comprehensive analytical report of genome, transcriptome, and proteome profiles in 373 patients diagnosed with endometrial carcinoma. 4 Additionally, this alliance decided four prognostic categories (from good to poor) for classification of endometrial carcinoma: (I) polymerase ɛ (POLE) hypermutation; (II) microsatellite instability (MSI) ultramutation; (III) lower copy number and (IV) higher copy number. However, in spite of advancements on early detection and better treatment options in the last few years, palindromia and metastasis can still occur leading to poor prognosis. 5 Therefore, it is desirable to further elucidate the molecular mechanisms that mediate endometrial carcinoma progression, especially metastasis.
As the most various classes of ion channels, the potassium channel can regulate numerous cellular functions in both stressful and non-stressful cells. Furthermore, due to its cell surface approachability, the potassium channel offers great therapeutic potential in many human diseases, including cancers. 6 The intermediate conductance Ca 2+ activated potassium channel Kca3.1, also known as SK4 or IK (encoded by the KCNN4 gene), is indispensable to maintain intracellular calcium homeostasis. 7, 8 The abnormal expression of Kca3.1 has been demonstrated to be associated with malignancy in most kinds of human cancers, such as pancreatic cancer, kidney cancer, ovarian cancer, colorectal cancer, breast cancer, lung cancer and glioblastoma. [9] [10] [11] [12] [13] [14] [15] [16] However, the role of Kca3.1 in the regulation in endometrial carcinoma remains to be further illustrated.
Long non-coding RNAs (lncRNAs) belong to a subgroup of noncoding RNAs that are at lowest 200 nucleotides in length and without protein-coding capacity. 17, 18 Across the previous studies, there are mounting evidences that the abnormal expression of long non-coding RNAs (lncRNAs) plays key roles in tumorigenesis and cancer metastasis. [19] [20] [21] [22] Moreover, the expression profilings of lncRNAs may facilitate the diagnosis and prognosis of human cancer, implying that lncRNAs may serve as efficacious therapeutic targets for intervention. Previous evidence also shows that several lncRNAs are important in the pathogenesis of endometrial carcinoma, including MALAT1, HOTAIR and H19. [23] [24] [25] [26] To be better understanding of molecular-level information provided by lncRNAs, we can inform diagnosis and therapy in endometrial carcinoma.
In the present study, the expression levels of Kca3.1 were found to be significantly up-regulated in endometrial carcinoma tissues compared to normal tissues, and correlations between Kca3.1 expression and different grades, stage were obtained from the datasets of TCGA (The Cancer Genome Atlas) project. Moreover, using RNA immunoprecipitation sequencing assay, we found that Kca3.1 may be highest targeted by lncRNA-14327.1, a part of an uncharacterized noncoding RNA LOC105378179. However, whether lncRNA-14327.1 is involved in the aberrant expression of Kca3.1, and the activation of EMT in endometrial carcinoma remains undiscovered. This study aimed to explore the function of lncRNA-14327.1 on Kca3.1regulation in endometrial carcinoma. We also investigated the relationship between lncRNA-14327.1, Kca3.1 and EMT in endometrial carcinoma, to seek a potential therapeutic target for endometrial carcinoma, particularly the metastatic one.
Materials and Methods

Clinical Specimens and Cell Culture
Twenty-five endometrial carcinoma biopsy specimens were collected from patients at the Zhejiang Cancer Hospital at the time of surgery and fixed in buffered formaldehyde solution, transferred to 70% ethanol, embedded in paraffin, sectioned into 5um sections and kept in -20°C. All patients provided a written informed consent for the use of these clinical materials in research, and the project was approved by the Institutional Ethics Committee of Zhejiang Cancer Hospital. The human endometrial carcinoma cell line HEC-1A was purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), and cultured in DMEM medium supplemented with 10% FBS. All cell lines were cultured in a humidified incubator in an atmosphere of 5% (v/v) CO 2 at 37°C.
Immunohistochemistry
Tissue slices were deparaffinage and dehydration. The activity of endogenous peroxidase was blocked with 3% hydrogen peroxide. Heat-induced antigen retrieval (HIER) was accomplished all slices in 0.01 M citrate buffer by using a steamer at 95°C. All primary antibodies were diluted with BSA to a concentration of 1:100 and applied to the slices. Incubation for 45 mins at room temperature followed by incubation with a DakoEnVision+System-HRP Labelled Polymer for 30 mins at room temperature. Diaminobenzidine was then applied for 10 mins. The slices were redyed with hematoxylin and then were dehydrated, covers lipped and visualized.
RNA Immunoprecipitation
The RIP assay was performed using a Thermo Fisher RIP kit (Thermo Fisher Scientific, MA, U.S.A) following the manufacturer's instructions. Briefly, the cell lysates in RIP lysis buffer and RNAs were incubated with the magnetic beads coupled with IgG or anti-Kca3.1 antibody at 4°C overnight. After the RNA was purified from the RIP production, lncRNAs were analyzed by high-throughput sequencing assay and validation was performed by qPCR assay.
Plasmid Construction and Transfection
The sequences of lncRNA-14327.1, lncRNA-14324.1, and lncRNA-14327.3 were synthesized and then subcloned into the vector pcDNA3.1 (Invitrogen, CA, USA), generating the overexpression vectors for pcDNA-14327.1, pcDNA-14324.1 and pcDNA-14327.3. The integrity of the respective plasmid constructs was confirmed by DNA sequencing. The plasmid formed a complex with Lipofectamine 2000 (Invitrogen) for 20 min at room temperature, and transfection was applied at 37°C for 24 h. The empty pcDNA3.1 vector was used as a contral. The expression of the lncRNAs was then determined by qPCR.
Generation of Stable Cell Lines with Overexpression of lncRNA-14327.1
For stably overexpressing lncRNA-14327.1, the lncRNA-14327.1 sequence was subcloned into the LV-13 (pLenti-EF1a-LUC-F2A-Puro-CMV) vector (GenePharma, Shanghai, China), and endometrial carcinoma cells were infected with the concentrated virus. Subsequently, cells were treated with 2 μg/mL puromycin for 2 weeks to select for stable cell line, in which the expression of lncRNA-14327.1 was validated by qPCR analysis.
RNA Interference of Kca3.1
Short interfering RNAs for Kca3.1 and non-targeting siRNAnegative control were obtained from GenePharma. Cells were transfected with siRNA using Lipofectamine 2000 reagent according to the manufacturer's instructions. Before any treatment, cells were incubated for 24 h or 48h and the silence efficiency of the siRNA was determined by Western blotting.
In vitro Migration and Invasion Assays
For the migration assay, a transwell system (24 wells, 8 μm pore size with a poly-carbonate membrane, Corning) was applied according to the manufacturer's protocols. Cells were seeded into the upper chambers and cultured in serum-free DMEM medium. The lower compartment was stuffed with 10% FBS in DMEM as a chemotactic factor. After incubation for 24 h, the cells that remained in the upper chamber were removed, and the cells at the bottom of the insert were fixed, stained in 0.5% crystal violet and counted under a microscope (Olympus Corp., Tokyo, Japan). The results were averaged over three independent experiments. For invasion assay, the invasion chambers were pre-coated with Matrigel (1:3 dilution; BD Biosciences) at 37°C for 30 min. The following steps were described as same as migration assay.
Western Blotting
Cells were lysed in RIPA buffer containing protease inhibitor cocktail (Sigma). After separation by electrophoresis on a 10% or 12% SDS-PAGE gel, proteins were transferred onto PVDF (polyvinylidene difluoride) membranes. Then, the membranes were blocked with 5% milk. After that, the membranes incubated with primary antibodies against Kca3.1, E-cadherin, N-cadherin, TIMP3 (all four from Abcam) at 4°C overnight. The corresponding HRP (horseradish peroxidase)-conjugated secondary antibody was incubated for 1 h at room temperature. Signals were visualized after chemiluminescence reaction with the HRP substrate. β-actin or GAPDH (CST) was applied as a loading control.
Cell Viability Assay
The cell viability was assayed in 96-well plates of endometrial carcinoma cell lines using the MTT assay. In brief, the pcDNA3.1, pcDNA-14327.1, pcDNA-14324.1 or pcDNA-14327.3 transfected cells were seeded into 96well plates at a density of 5000 cells/well and allowed to incubate for 24 h and 48 h. After that, the cells followed by the MTT assay to determine cell survival rates. The absorbance of each sample was read at 570 nm using a microplate reader. For the cell viability of stable cell lines with overexpression of lncRNA-14327.1 was the same progresses as above.
Cell Cycle Analysis
After treated, cells were harvested and washed with 1×PBS (phosphate-buffered saline) and fixed in 75% ethanol at −20°C. The fixed cells were washed with 1×PBS, incubated for 30 min at 37°C with RNase A (100 µg/mL) and 0.1% TritonX-100, stained with propidium iodide (30 μg/mL), and analyzed by flow cytometry (FACS Calibur, BD Biosciences). The percentages of cells at G1, S, and G2/M were calculated by the FlowJo software program (Flowjo, LLC) based on the DNA content.
Intracellular Ca2+ Levels
To measure intracellular Ca2+ levels, the Calcium Assay Kit from Abcam was used according to the manufacturer's protocols.
Statistical Analysis
All data are expressed as the means ± S.D. from at least three independent experiments. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) software packages. Statistical significance was determined using two-sided Student's t-test, and P < 0.05 (*) was considered significant.
Results
Relationship Between Kca3.1 Expression and Characteristics of Clinical Pathological in Endometrial Carcinoma Patients
To investigate the clinical relevance of Kca3.1 in endometrial carcinoma, we first analyzed the TCGA database and found that the expression level of Kca3.1 was much higher in endometrial carcinoma tissue than in adjacent normal tissues ( Figure 1A) . Moreover, high Kca3.1 expression was associated with advanced tumor-node-metastasis (TNM) stage ( Figure 1B) .
To explore whether the Kca3.1 expression profiling in clinical specimens was consistent with the database, the Kca3.1 protein level in 25 paired normal tissues and endometrial carcinoma tissues was detected by Immunohistochemistry. These analyses revealed that the protein level of Kca3.1 was significantly upregulated in endometrial carcinoma tissues compared with the normal counterparts ( Figure 1C , representative results were shown). Taking together, these results indicated that the upregulation of Kca3.1 might play a crucial role in endometrial carcinoma development and progression. To determine the association between lncRNA and Kca3.1 in endometrial carcinoma, RNA immunoprecipitation (RIP) was carried out in HEC-1A cells. Using a specifically Kca3.1 targeted antibody to pull down the complex, followed by RNA seq and qPCR validation. In the Kca3.1 antibody group, the content of lncRNA ranked in the top three are presented (Table 1) .
To further explore the biological role of these three lncRNAs in endometrial carcinoma, we first constructed their overexpression plasmids and examined the transfection efficiency in HEC-1A cells and observed that pcDNA-14327.1, pcDNA-14324.1 and pcDNA-14327.3 were highly expressed after transfection for both 24h and 48h compared with the empty vector control (Figure 2A) . The sequences for the primers used are listed in Table 2 . Next, Western blot assay was used to analyze the protein levels of Kca3.1 in the HEC-1A cells that transfected with pcDNA-14327.1, pcDNA-14324.1, pcDNA-14327.3 and pcDNA3.1, respectively. As shown in Figure 2B , all three lncRNAs could upregulate the protein expression of Kca3.1, but the cells transfected with pcDNA-14327.1 expressed the highest level of Kca3.1. However, the results of the MTT assay revealed that the lncRNA-14327.1, lncRNA-14324.1and lncRNA-14327.3 overexpression significantly inhibited cell proliferation ( Figure 2C ).
To further examine the effect on the tumor behavior of lncRNA-14327.1, lncRNA-14324.1 and lncRNA-14327.3 overexpression in endometrial carcinoma cells, migration ability was measured by the transwell assays. As shown in Figure 2D To further elucidate the function of lncRNA-14327.1 in endometrial carcinoma cells in vitro, we constructed the lncRNA-14327.1 stably overexpressed HEC-1A cell line and its control using the lentivirus system, and the lncRNA-14327.1 expression level in stable HEC-1A cells was determined by qPCR assay ( Figure 3A) . Next, the stable HEC-1A cells were analyzed by Western blot. As expected, a significant increase in protein level of Kca3.1 in the lenti-14327.1 group compared with those observed in the lenti-control group ( Figure 3B) .
To confirm the effect of increasing endogenous lncRNA-14327.1 expression on Kca3.1 protein degradation, we compared the half life time of Kca3.1 protein between lncRNA-14327.1 stably overexpressed HEC-1A cell line and its control. The stability of Kca3.1 protein was found to be upregulated more than twofold after overexpression of lncRNA-14327.1 compared with the control cells in a CHX pulse-chase assay ( Figure 3C ). Since Kca3.1 is a regulator of intracellular Ca 2+ , we next tested whether upregulation of Kca3.1 following stable lenti-14327.1 expression was associated with intracellular Ca 2+ homeostasis. As expected, a remarkable enhancement of intracellular concentration of Ca 2+ in the lenti-14327.1 group compared with those in the lenti-control group was observed ( Figure 3D ). Taken together, our results suggested that the lncRNA-14327.1 could indeed stabilize Kca3.1 protein and finally increase the intracellular concentration of Ca 2+ in HEC-1A cells. The lncRNA-14327.
Promotes Endometrial Carcinoma Cell Migration and Invasion
Next, we detected the function of lncRNA-14327.1 in cell behavior in HEC-1A cells with stable expression of lncRNA-14327.1. As shown in Figure 4A and B, stable expression of lncRNA-14327 significantly increased cells migration and invasion abilities compared to the control group. Subsequently, the results of the MTT assay proved that the stable expression of lncRNA-14327.1 significantly inhibited cell proliferation, which was consistent with the result from the experiments with transient transfection ( Figure 4C ). Inhibition of tumor cell growth is frequently related to cell cycle arrest. Therefore, we investigated the influence of lncRNA-14327.1 stable expression on the cell cycle distribution in endometrial carcinoma cell lines by Flow cytometry. The results showed that stable expression of lncRNA-14327 reduced cell cycle distribution in the S/ M fraction and no significant difference in G0/G1 and G2/ M ( Figure 4D) . Combined results suggested that stable expression of lncRNA-14327 promoted endometrial carcinoma cell migration and invasion, but suppressed cell proliferation by inducing cell cycle.
The Couple of lncRNA-14327.1 and Kca3.1 Promoted Endometrial Carcinoma Cells Migration and Invasion by Inducing EMT
To define the role of lncRNA-14327.1 and Kca3.1 in the progression of cell metastasis in endometrial carcinoma, we treated the lenti-14327.1 HEC-1A cells with siRNA of Kca3.1. Firstly, lenti-14327.1 HEC-1A cells were associated with the decrease of the epithelium marker E-cadherin and TIMP3, an inhibitor of metalloproteinases, but the increase of mesenchymal markers N-cadherin compared with those observed in the lenti-control group ( Figure 5A ). As shown in Figure 5B , Kca3.1 was effectively down-regulated in Kca3.1-siRNA-2 transfected cells. Next, to determine whether lncRNA-14327.1 induced endometrial carcinoma cells EMT, cell migration and invasion via coupling with Kca3.1, we made use of a Kca3.1 silence model. As shown in Figure 5C and D, we found that inhibition of Kca3.1 not only significantly decreased cell migration and invasion in the lenti-control group but also attenuated the pro-effects of lncRNA-14327.1 on cell migration and invasion. In addition, the silence of Kca3.1 inhibited the expression of two classical mesenchymal cell markers (N-cadherin) in lenti-14327.1 cells, whereas the epithelial cell marker E-cadherin and metalloproteinases inhibitor TIMP3 was elevated ( Figure 5E ). Taken together, all these results suggested that the lncRNA-14327.1 promoted the migration and invasion potential of endometrial carcinoma cells by upregulating Kca3.1 at least partially.
Discussion
The data from TCGA dataset revealed that the expression of Kca3.1 mRNA was upregulated in endometrial carcinoma tissues compared to adjacent noncancerous tissues and positively associated with the tumor stages. Our data from immunohistochemistry analysis also showed that the expression of Kca3.1 protein was higher expressed in endometrial carcinoma tissues compared to adjacent noncancerous tissues. Although the roles of Kca3.1 in several cancer types have been documented, the regulation mechanism for Kca3.1 expression in endometrial carcinoma remains to be illustrated, especially the role of long non-coding RNA. The discovery of lncRNA, do not exhibit proteincoding potential, was a breakthrough in regulating the 
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OncoTargets and Therapy 2019:12 expression of eukaryotic genome and inducing the anomaly growth and metastasis of cancer. 27, 28 Operation of the expression of lncRNA could affect the cell migration and invasion, cell proliferation, cell cycle and so on of cell behavior in various cancers. 29 First of all, we verified three lncRNAs, including lncRNA-14327. For further elucidation for the underlying mechanism, HEC-1A cell line with stable expression of lncRNA-14327 and its control cell line were constructed with lentivirus.
Our results showed that stably high expression of lncRNA-14327.1 could effectively induce endometrial carcinoma cell migration and invasion with Kca3.1 upregulated. Moreover, knockdown of Kca3.1 could partially reverse the biological response to the overexpression of lncRNA-14327.1. Therefore, our data indicated lncRNA-14327.1 might promote endometrial carcinoma progression through targeting Kca3.1. Additionally, the stability of Kca3.1 protein was found to be upregulated more than twofold after overexpression of lncRNA-14327.1 in a CHX pulse-chase assay. Noticeably, a remarkable enhancement in the concentration of intracellular concentration of Ca 2+ in the lenti-14327.1 group was observed compared with those in the lenti-control group. Overall, these data clearly demonstrated that lncRNA-14327.1 could stabilize Kca3.1 to increase the intracellular concentration of Ca 2+ .
One of several steps involved in metastasis is epithelialmesenchymal transition (EMT). 30 As shown in Figure 5 , we found that downregulation of Kca3.1 inhibited the expression of classical mesenchymal cell markers N-cadherin in lenti-14327.1 cells, whereas the epithelial cell marker E-cadherin and metalloproteinases inhibitor TIMP3 was elevated. Combined results suggested that the couple of lncRNA-14327.1 and Kca3.1 might induce endometrial carcinoma cells metastasis by promoting the EMT.
Conclusion
In conclusion, our findings suggest that lncRNA-14327.1 functions as a novel oncogene to regulate the cell migration and invasion of endometrial carcinoma cells by stabilizing the Kca3.1protein and subsequently activating the EMT. Therefore, the lncRNA-14327.1/Kca3.1 axis may be a novel molecular therapeutic target for the treatment of endometrial carcinoma, especially the metastatic one.
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